Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms

The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the com...

Descripción completa

Detalles Bibliográficos
Autores: Torrens, G, Cabot, G, Ocampo-Sosa, AA, Conejo, MC, Zamorano, L, Navarro, F, Pascual, A, Martinez-Martinez, L, Oliver, A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p7016
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7016
https://europepmc.org/articles/pmc5038310
Access Level:acceso abierto
id ES_aaf97e9d1d6a67b54968cfcf3f072a9d
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p7016
network_acronym_str ES
network_name_str España
repository_id_str
spelling Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance MechanismsTorrens, GCabot, GOcampo-Sosa, AAConejo, MCZamorano, LNavarro, FPascual, AMartinez-Martinez, LOliver, AThe activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at <= 4 mu g/ ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant beta-lactam resistance mechanisms.AMER SOC MICROBIOLOGY2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7016https://europepmc.org/articles/pmc5038310ANTIMICROBIAL AGENTS AND CHEMOTHERAPYISSN: 00664804ISSNe: 10986596reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p70162026-06-14T12:41:47Z
dc.title.none.fl_str_mv Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
title Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
spellingShingle Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
Torrens, G
title_short Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
title_full Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
title_fullStr Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
title_full_unstemmed Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
title_sort Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant beta-Lactam Resistance Mechanisms
dc.creator.none.fl_str_mv Torrens, G
Cabot, G
Ocampo-Sosa, AA
Conejo, MC
Zamorano, L
Navarro, F
Pascual, A
Martinez-Martinez, L
Oliver, A
author Torrens, G
author_facet Torrens, G
Cabot, G
Ocampo-Sosa, AA
Conejo, MC
Zamorano, L
Navarro, F
Pascual, A
Martinez-Martinez, L
Oliver, A
author_role author
author2 Cabot, G
Ocampo-Sosa, AA
Conejo, MC
Zamorano, L
Navarro, F
Pascual, A
Martinez-Martinez, L
Oliver, A
author2_role author
author
author
author
author
author
author
author
description The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at <= 4 mu g/ ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant beta-lactam resistance mechanisms.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7016
https://europepmc.org/articles/pmc5038310
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7016
https://europepmc.org/articles/pmc5038310
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv AMER SOC MICROBIOLOGY
publisher.none.fl_str_mv AMER SOC MICROBIOLOGY
dc.source.none.fl_str_mv ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN: 00664804
ISSNe: 10986596
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416227771777024
score 15,811543

Similares en LA Referencia